0001127602-20-007625.txt : 20200225 0001127602-20-007625.hdr.sgml : 20200225 20200225162809 ACCESSION NUMBER: 0001127602-20-007625 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200221 FILED AS OF DATE: 20200225 DATE AS OF CHANGE: 20200225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: STAAB THOMAS R II CENTRAL INDEX KEY: 0001230708 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 20651054 MAIL ADDRESS: STREET 1: C/O INSPIRE PHARMACEUTICALS, INC. STREET 2: 4222 EMPEROR BLVD., SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2020-02-21 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001230708 STAAB THOMAS R II 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703 1 Senior Vice President and CFO Emp. Stock Option (Right to Buy) 11.13 2020-02-21 4 A 0 18000 0 A 2020-02-21 2024-12-22 Common Stock 18000 18000 D On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested. /s/ Alane P. Barnes, by power of attorney 2020-02-25